deferasirox has been researched along with senicapoc in 1 studies
| Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (senicapoc) | Trials (senicapoc) | Recent Studies (post-2010) (senicapoc) |
|---|---|---|---|---|---|
| 832 | 136 | 572 | 42 | 3 | 32 |
| Protein | Taxonomy | deferasirox (IC50) | senicapoc (IC50) |
|---|---|---|---|
| Intermediate conductance calcium-activated potassium channel protein 4 | Homo sapiens (human) | 0.009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okpala, I | 1 |
1 review(s) available for deferasirox and senicapoc
| Article | Year |
|---|---|
Investigational agents for sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Animals; Antihypertensive Agents; Antisickling Agents; Benzaldehydes; Benzoates; Carnitine; Cell Adhesion; Deferasirox; Endothelium, Vascular; Etilefrine; Female; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Hypertension, Pulmonary; Iron Chelating Agents; Male; Membrane Glycoproteins; Potassium Channels, Calcium-Activated; Priapism; Recombinant Fusion Proteins; Triazoles; Trityl Compounds; Vasoconstrictor Agents | 2006 |